Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide

Eiji Matsukuma; Yusuke Aoki; Miho Sakai; Norio Kawamoto; Hiroh Watanabe; Shigeki Iwagaki; Yuichiro Takahashi; Ichiro Kawabata; Naomi Kondo; Yasushi Uchida

doi:10.1016/j.jpedsurg.2008.12.008

Treatment with OK-432 for persistent congenital chylothorax in newborn infants resistant to octreotide

J Pediatr Surg. 2009 Mar;44(3):e37-9. doi: 10.1016/j.jpedsurg.2008.12.008.

Authors

Eiji Matsukuma¹, Yusuke Aoki, Miho Sakai, Norio Kawamoto, Hiroh Watanabe, Shigeki Iwagaki, Yuichiro Takahashi, Ichiro Kawabata, Naomi Kondo, Yasushi Uchida

Affiliation

¹ The Department of Pediatrics, Nagara Medical Center, Gifu 502-8558, Japan.

PMID: 19302843
DOI: 10.1016/j.jpedsurg.2008.12.008

Abstract

Chylothorax is a relatively uncommon condition defined as an abnormal collection of lymphatic fluid within the pleural space. We are reporting the use of OK-432 for treatment of prolonged idiopathic congenital chylothorax in 2 newborn infants who failed to respond to conservative medical therapy, including octreotide injection.

MeSH terms

Antineoplastic Agents / administration & dosage
Antineoplastic Agents / therapeutic use*
C-Reactive Protein / analysis
Chest Tubes
Chylothorax / congenital
Chylothorax / drug therapy*
Chylothorax / therapy
Female
Humans
Infant, Newborn
Instillation, Drug
Male
Octreotide / administration & dosage
Picibanil / administration & dosage
Picibanil / therapeutic use*
Pleural Effusion / drug therapy
Respiration, Artificial
Treatment Failure

Substances

Antineoplastic Agents
Picibanil
C-Reactive Protein
Octreotide